Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA4 | P22748 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | MIF | P14174 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1-Methoxy-2-Butoxybenzene SCHEMBL31085542 | 1.00 | L3MBTL1 (0.63) | L3MBTL1TDP1CYP1A2CYP2C9CYP2C19 | |
| 1-Methoxy-2-Pentoxybenzene SCHEMBL15086389 | 0.94 | L3MBTL1 (0.67) | L3MBTL1TDP1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL8077873 | 0.92 | ALDH1A1 (0.67) | L3MBTL1TDP1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL14382275 | 0.92 | ALDH1A1 (0.67) | L3MBTL1TDP1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5614161 | 0.92 | ALDH1A1 (0.67) | L3MBTL1TDP1CYP1A2CYP2C9CYP2C19 | |
| 1,2-Dibutoxybenzene SCHEMBL29428927 | 0.91 | CYP1A2 (0.72) | L3MBTL1TDP1CYP1A2CYP2C9CYP2C19 | |
| 1,2-Dibutoxybenzene SCHEMBL1226749 | 0.91 | CYP1A2 (0.72) | L3MBTL1TDP1CYP1A2CYP2C9CYP2C19 | |
| 1-Methoxy-2-Propoxybenzene SCHEMBL791386 | 0.89 | L3MBTL1 (0.60) | L3MBTL1TDP1ALDH1A1TP53CA12 | |
| 1-Methoxy-2-Propoxybenzene SCHEMBL30827433 | 0.89 | L3MBTL1 (0.60) | L3MBTL1TDP1ALDH1A1TP53CA12 | |
| 1,2-Dibutoxybenzene SCHEMBL6236324 | 0.89 | CYP1A2 (0.69) | L3MBTL1TDP1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019030643-A1 | COMPOSITIONS OF EUGENOL DERIVATIVES FOR TREATMENT OF VISCERAL LEISHMANIASIS | FOUNDATION FOR NEGLECTED DISEASE RESEARCH (IN) | 2019-02-14 | — | — | WO | claimed |
| EP-0546237-A1 | Method for lubrication and sealing of cork stoppers with silico-paraffin and plasto-silico-paraffin compounds | LA TECNOCHIMICA S.A.S. DI UGO MESTRALLET & C. (IT) | 1993-06-16 | — | — | EP | claimed |
| WO-2021076020-A2 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PROPHYLAXIS OF INFECTIOUS INFLAMMATORY DISEASES | ГАПОНОВ, Андрей Михайлович | 2021-04-22 | — | — | WO | disclosed |
| EP-3461556-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | AbbVie Ireland Unlimited Company (IE) | 2019-04-03 | — | — | EP | disclosed |
| EP-2593226-B1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBVIE IRELAND UNLIMITED CO (IE) | 2018-11-14 | — | — | EP | disclosed |
| US-20170210761-A1 | 9H-PYRIMIDO [4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-07-27 | — | — | US | disclosed |
| US-9669399-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9669399-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9669399-B2 | Phosphine ligands for catalytic reactions | ABBVIE INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9580430-B2 | 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160263566-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | ABBVIE INC. | 2016-09-15 | — | — | US | disclosed |
| US-20100230647-A1 | COMPOUND OR ITS TAUTOMER, METAL COMPLEX COMPOUND, COLORED PHOTOSENSITIVE CURING COMPOSITION, COLOR FILTER, AND PRODUCTION | FUJIFILM CORPORATION (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20080242687-A1 | SUBSTITUTED PYRIMIDINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| WO-2007123699-A1 | METHODS AND COMPOSITIONS FOR MODULATING MELANOGENESIS BY USING A MCLR AGONIST | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007076161-A2 | COMPOUNDS WITH THERAPEUTIC ACTIVITY | MYRIAD GENETICS, INC (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-1995003712-A1 | EMULSION CONCENTRATE | GOLDENBERG VIKTOR ILIICH (RU) | 1995-02-09 | — | — | WO | disclosed |
| EP-0546237-A1 | Method for lubrication and sealing of cork stoppers with silico-paraffin and plasto-silico-paraffin compounds | LA TECNOCHIMICA S.A.S. DI UGO MESTRALLET & C. (IT) | 1993-06-16 | — | — | EP | disclosed |
| EP-0154959-A2 | Complete, integrated liquid feed for livestock use | DOX-AL ITALIA S.p.A. (IT) | 1985-09-18 | — | — | EP | disclosed |
| US-4233161-A | CARRIERS FOR PERFUME, MOTHPROOFING AGENT, OR DEODORANT | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1980-11-11 | — | — | US | disclosed |
| US-4208182-A | PRETREATMENT OF AN ACETATE WITH AN AMINE; DISPERSE DYES; FADING INHIBITION | TOYO INK MANUFACTURING CO., LTD. (JP) | 1980-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263566-A1 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS | PHOSPHO1, PLCG2, PPIP5K2 | L3MBTL1 2677/4885TDP1 1299/4885CYP1A2 3435/4885 |
| US-20170210761-A1 | 9H-PYRIMIDO [4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | L3MBTL1 1141/4885TDP1 395/4885CYP1A2 1598/4885 |
| US-20100230647-A1 | COMPOUND OR ITS TAUTOMER, METAL COMPLEX COMPOUND, COLORED PHOTOSENSITIVE CURING COMPOSITION, COLOR FILTER, AND PRODUCTION | CRY1, IK, PRMT5 | L3MBTL1 4079/4885TDP1 2916/4885CYP1A2 538/4885 |
| US-20080242687-A1 | SUBSTITUTED PYRIMIDINES | EDNRB, EDNRA, ECE1 | L3MBTL1 4881/4885TDP1 350/4885CYP1A2 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.